Members of our Life Sciences Group and MDR Cyber team will be joined by Guest Speaker Dr Yuri Martina, Senior Vice President of Development at Grünenthal Group, to explore the implications of applying emerging technologies to clinical trials and the disruptive impact on drug development processes. The panel will also be discussing how businesses integrate machine learning and the potential impact of Brexit on the conduct of clinical trials in the UK after the end of the transition period.
The session will be chaired by Martyn Hann, Head of Life Sciences at Mishcon de Reya LLP.